Krystal Biotech, Inc.
KRYS
Kedudukan dalam Saham
#2151
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Harga Saham
$320.50
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$9.49B
Perubahan (1 hari)
1.24%
Perubahan (1 tahun)
63.55%
Negara
US
Perdagangan Krystal Biotech, Inc. (KRYS)
Kategori
Healthcare
Pendapatan untuk Krystal Biotech, Inc. (KRYS)
Pendapatan pada Jun 2026 TTM: $226.62M
Menurut laporan kewangan terkini Krystal Biotech, Inc., pendapatan semasa syarikat ialah $226.62M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $12.90M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $-139.98M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Krystal Biotech, Inc. dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $226.62M | 137.66% |
| 2024 | $95.36M | 639.37% |
| 2023 | $12.90M | -109.21% |
| 2022 | $-139.98M | 101.20% |
| 2021 | $-69.57M | 116.28% |
| 2020 | $-32.17M | 68.52% |
| 2019 | $-19.09M | 75.30% |
| 2018 | $-10.89M | 37.49% |
| 2017 | $-7.92M | 588.70% |
| 2016 | $-1.15M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | 2,227.64% |
US
|
|
| $-3.09B | -1,462.19% |
US
|
|
| $-4.02B | -1,872.22% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 760.76% |
NL
|
